Galecto Biotech AB

Non-Small Cell Lung Cancer

Clinical research in non-small cell lung cancer focuses on GB1211, a galectin-3 inhibitor, studied in combination with atezolizumab in patients with advanced disease. The programme examines antitumor activity, lesion response, and treatment-related safety in NSCLC.

  • Immuno-oncology combinations
  • Galectin-3 inhibition
  • Tumor response assessment
  • Long-term safety

This area reflects a focus on lung cancer therapies that integrate targeted pathways with immune checkpoint inhibition.

Advanced Liver Fibrosis and Cirrhosis

Research activity also extends to advanced liver fibrosis and cirrhosis, with interest in disease mechanisms linked to fibrotic progression and hepatic remodeling. The therapeutic emphasis is on conditions where fibrosis drives worsening liver function and clinical burden.

  • Hepatic fibrosis
  • Cirrhotic liver disease
  • Fibrosis-related pathways
  • Liver disease progression

The sponsor’s portfolio includes liver-directed investigation in severe chronic disease settings.

Pharmacokinetics and Formulation Research

Another research focus is the pharmacokinetic profile of GB1211, including comparisons between tablet and capsule formulations and evaluation under fasted and fed conditions. This work addresses drug absorption and exposure characteristics in healthy volunteers.

  • Oral formulation comparison
  • Food effect
  • Bioavailability
  • Healthy volunteer studies

The research supports development in oral small-molecule therapeutics with attention to dosing convenience and systemic exposure.

Immunotherapy and Targeted Oncology

The sponsor’s oncology work centers on combining a targeted anti-fibrotic mechanism with immunotherapy, particularly atezolizumab, in solid tumors. The therapeutic interest lies in improving disease control through modulation of tumor-associated pathways.

  • Checkpoint inhibitor combinations
  • Solid tumor therapy
  • Targeted immune modulation
  • Oncology biomarker activity

This area highlights a cross-disciplinary interest in cancer biology and immune-based treatment strategies.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study comparing how the body processes GB1211 capsule and tablet forms with and without food in healthy volunteers

    Not recruiting

    1 1
    Investigated diseases:
    The Netherlands
  • Study on the Safety and Effectiveness of GB1211 and Atezolizumab for Patients with Non-Small Cell Lung Cancer

    Not recruiting

    1 1
    France Spain